Press releases June 23, 2020 Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement March 30, 2020 Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137 February 28, 2020 Compass Therapeutics to Present at the 40th Cowen Health Care Conference January 6, 2020 Compass Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference December 2, 2019 Compass Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference October 24, 2019 Compass Therapeutics to Present Preclinical Data on a Novel PD-1/PD-L1 Bispecific Antibody and from its Proprietary Innate Cell Engager Platform at the 2019 SITC Meeting October 22, 2019 Compass Therapeutics Appoints Leading Immuno-Oncology Researchers to Its Immuno-Oncology Scientific Advisory Board August 1, 2019 Compass Therapeutics Appoints Julie Sunderland to Board of Directors July 8, 2019 Compass Therapeutics Announces First Patient Dosed in Phase 1 Trial of CTX-471 June 17, 2019 Compass Therapeutics Announces Issuance of Composition of Matter and Method Patents Covering Its Lead Immuno-oncology Candidate, CTX-471 March 24, 2019 Compass at Keystone’s Cancer Immunotherapy Symposium (March 24-28) in Keystone, Colorado March 12, 2019 Compass at the Cowen & Co. 39th Annual Health Care Conference 2019 January 3, 2019 Compass Therapeutics to Present at J.P. Morgan Healthcare Conference November 26, 2018 Compass Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference November 6, 2018 Compass Therapeutics Announces Preclinical Data on Lead Antibody Program and NK Cell Engager Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting October 2, 2018 FierceBiotech Names Compass Therapeutics a 2018 “Fierce 15” Biotech Company July 12, 2018 Compass Therapeutics Completes $132 Million Series A Financing To Advance Next-Generation Antibody-Based Therapeutics Into The Clinic
